Please login to the form below

Not currently logged in
Email:
Password:

Crysvita

This page shows the latest Crysvita news and features for those working in and with pharma, biotech and healthcare.

GSK’s anti-BCMA drug leads crowded CHMP recommendations

GSK’s anti-BCMA drug leads crowded CHMP recommendations

received a positive opinion for Crysvita (burosumab) for the treatment of older adolescents and adults living with the rare diseases X-linked hypophosphataemia.

Latest news

  • SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease SMC enables access to Kyowa Kirin’s Crysvita for rare bone disease

    The trial evaluated Crysvita in comparison to conventional therapy with oral phosphate and active vitamin D. ... An application for the extended use of Crysvita in adults with XLH is also currently under review by the EMA.

  • NICE U-turn on Crystiva for rare bone disease NICE U-turn on Crystiva for rare bone disease

    Tom Stratford, CEO, Kyowa Kirin International said: It is a major development that NICE has recommended Crysvita for routine use among children and young people with XLH in England and Wales. ... Crysvita targets this pathway by blocking the activity of

  • Orphan drugs dominate UK Prix Galien shortlist, medtech debuts Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

    Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

  • NICE set to reject Kyowa Kirin’s Crysvita for XLH NICE set to reject Kyowa Kirin’s Crysvita for XLH

    is set to receive a NICE rejection for its rare disease therapy Crysvita (burosumab). ... Crysvita’s annual pricing is conditional on the patient’s weight but has an upper estimated price of an eye watering £388, 960 a year for a 17-year-old

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... Ultragenyx’s FDA approval was for Crysvita (burosumab), which has become the first approved drug for adults and children ages one year and older with X-linked

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....